{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,29]],"date-time":"2026-06-29T11:19:13Z","timestamp":1782731953401,"version":"3.54.5"},"reference-count":19,"publisher":"BMJ","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["BMJ Case Reports"],"abstract":"<jats:p>Antibiotic use in infection with Shiga-toxin-producing strains of<jats:italic>Escherichia coli<\/jats:italic>(<jats:italic>E coli<\/jats:italic>) is thought to increase the risk of developing haemolytic-uraemic syndrome (HUS). One paediatric study concluded that<jats:italic>E coli<\/jats:italic>O157:H7-infected patients who had received antibiotic therapy were 17 times more likely to progress to HUS than those who had not. Quinolones are among those incriminated. In vitro experiments suggest toxin induction of 80-fold with ciprofloxacin and<jats:italic>E coli<\/jats:italic>O104:H4. We report here the case of a 44-year-old man returning from Hamburg who presented with a 5\u2005day history of bloody diarrhoea which had worsened after starting ciprofloxacin. A severe illness of overlapping HUS and thrombotic thrombocytopaenic purpura (TTP) ensued, with neurological complications requiring ventilation and intensive care admission. Stool sample eventually confirmed<jats:italic>E coli<\/jats:italic>O104:H4. Although the patient made a good recovery following treatment with haemofiltration and plasma exchange with fresh frozen plasma (FFP), ciprofloxacin may have exacerbated his clinical course.<\/jats:p>","DOI":"10.1136\/bcr-2012-006896","type":"journal-article","created":{"date-parts":[[2012,12,22]],"date-time":"2012-12-22T08:37:04Z","timestamp":1356165424000},"page":"bcr2012006896","source":"Crossref","is-referenced-by-count":3,"title":["Microbes without frontiers: severe haemolytic-uraemic syndrome due to<i>E coli<\/i>O104:H4"],"prefix":"10.1136","volume":"2012","author":[{"given":"Sophie","family":"Binks","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kate","family":"Regan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jonathan","family":"Richenberg","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tim","family":"Chevassut","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"239","published-online":{"date-parts":[[2012,12,21]]},"reference":[{"key":"2025042707594718000_2012.dec21_1.bcr2012006896.1","doi-asserted-by":"publisher","DOI":"10.1001\/jama.290.10.1360"},{"key":"2025042707594718000_2012.dec21_1.bcr2012006896.2","doi-asserted-by":"crossref","unstructured":"Michael M Elliott EJ Ridley GF . Interventions for haemolytic uraemic syndrome and thrombotic thrombocytopaenic purpura. Cochrane Database Syst Rev 2009;(1):CD003595.","DOI":"10.1002\/14651858.CD003595.pub2"},{"key":"2025042707594718000_2012.dec21_1.bcr2012006896.3","unstructured":"Health Protection Agency. E. coli O157 annual totals (on-line). 2012. http:\/\/www.hpa.org.uk\/web\/HPAweb&HPAwebStandard\/HPAweb_C\/1249113624846 (accessed 4 Jun 2012)."},{"key":"2025042707594718000_2012.dec21_1.bcr2012006896.4","doi-asserted-by":"publisher","DOI":"10.1086\/315239"},{"key":"2025042707594718000_2012.dec21_1.bcr2012006896.5","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1106920"},{"key":"2025042707594718000_2012.dec21_1.bcr2012006896.6","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(11)61145-8"},{"key":"2025042707594718000_2012.dec21_1.bcr2012006896.7","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(05)71144-2"},{"key":"2025042707594718000_2012.dec21_1.bcr2012006896.8","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(11)61253-1"},{"key":"2025042707594718000_2012.dec21_1.bcr2012006896.9","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.01783-09"},{"key":"2025042707594718000_2012.dec21_1.bcr2012006896.10","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(99)00621-2"},{"key":"2025042707594718000_2012.dec21_1.bcr2012006896.11","doi-asserted-by":"publisher","DOI":"10.1111\/j.1469-0691.2007.01947.x"},{"key":"2025042707594718000_2012.dec21_1.bcr2012006896.12","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.01401-10"},{"key":"2025042707594718000_2012.dec21_1.bcr2012006896.13","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.06315-11"},{"key":"2025042707594718000_2012.dec21_1.bcr2012006896.14","doi-asserted-by":"publisher","DOI":"10.1056\/NEJM200006293422601"},{"key":"2025042707594718000_2012.dec21_1.bcr2012006896.15","doi-asserted-by":"publisher","DOI":"10.1345\/aph.1A350"},{"key":"2025042707594718000_2012.dec21_1.bcr2012006896.16","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.e4565"},{"key":"2025042707594718000_2012.dec21_1.bcr2012006896.17","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.e4598"},{"key":"2025042707594718000_2012.dec21_1.bcr2012006896.18","unstructured":"British National Formulary. BNF 63. London: BMJ group and RPS publishing, 2012."},{"key":"2025042707594718000_2012.dec21_1.bcr2012006896.19","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMc1100859"}],"container-title":["BMJ Case Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.1136\/bcr-2012-006896","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,4,27]],"date-time":"2025-04-27T14:59:56Z","timestamp":1745765996000},"score":1,"resource":{"primary":{"URL":"https:\/\/casereports.bmj.com\/lookup\/doi\/10.1136\/bcr-2012-006896"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2012,12,21]]},"references-count":19,"alternative-id":["10.1136\/bcr-2012-006896"],"URL":"https:\/\/doi.org\/10.1136\/bcr-2012-006896","relation":{},"ISSN":["1757-790X"],"issn-type":[{"value":"1757-790X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2012,12,21]]}}}